Last update July 2, 2015

Sibutramine

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

On latest update relevant published data on breastfeeding were not found.

Because of high protein-binding, excretion into breast milk seems unlikely.

Medication used as anorexigen. Amphetamine-like drug that acts as reuptake inhibitor of Serotonin, Norepinephrine and Dopamine. May cause increase of Prolactin and Galactorrhea.

Because of cardiovascular side effects (Arrhythmia, Hypertension, Heart infarction) several regulatory agencies (EMEA, FDA) have withdrawn it from the market in many countries.

Breastfeeding mothers return to their pre- pregnancy body weight sooner than others who don't.

Alternatives

  • Hypocaloric Diet ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Orlistat (Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Sibutramine in other languages or writings:

Group

Sibutramine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Sibutramine in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 77 %
Molecular weight 334 daltons
Protein Binding 94 - 97 %
Tmax 1 - 3 hours
1 - 16 hours

References

  1. Soares Leaes CG, Pereira-Lima JF, da Costa Oliveira M. A case of sibutramine-induced hyperprolactinemia. Neuro Endocrinol Lett. 2011 Abstract
  2. FDA. FDA Recommends Against the Continued Use of Meridia (sibutramine). FDA Drug Safety Communication. 2010 Full text (link to original source) Full text (in our servers)
  3. MHRA (UK). Sibutramine: Suspension of marketing authorisation as risks outweigh benefits. Safety warnings and messages for medicines. 2010 Full text (link to original source) Full text (in our servers)
  4. EMEA. European Medicines Agency recommends suspension of marketing authorisations for sibutramine. Press Office. 2010 Full text (link to original source) Full text (in our servers)
  5. Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int J Obes (Lond). 2008 Abstract Full text (link to original source) Full text (in our servers)
  6. Sibutramina. Ficha técnica. 2000 Full text (in our servers)
  7. Sibutramine. Drug Summary. 2000 Full text (in our servers)

Total visits

28,319

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM